Nico Surdo is Head of Clinical Trial Services (CTS) at PHOENIX Group, one of Europe’s leading healthcare providers. With more than 10 years of experience in the clinical trials industry, he has held international roles across the sector, including several years with a global CDMO organization.
At PHOENIX, Nico is responsible for the strategic development, harmonization, and expansion of Clinical Trial Services across the Group. His scope covers multiple CTS business areas, including Comparator Sourcing, GMP Services, Depot & Distribution, Patient Recruitment, and Pharmacy Services. He is passionate about building scalable, patient-centric solutions and strengthening the role of community pharmacies within the clinical trial ecosystem.
Laura has over 12 years’ experience in clinical research including complex and adaptive Phase 1, First In Human/pharmacology, drug-drug interactions, bioequivalence and scintigraphy, as single and multicentred studies, across numerous clinical indications in both healthy and patient populations.
She previously supported pre-hospital research at the Welsh Ambulance Service and coordinated Phase III and IV commercial and non-commercial trials across several therapeutic areas within the NHS.
Dr Danielle Webb has over 13 years’ experience in clinical research, with expertise in the design, management, analysis and reporting of first-in-human, Phase I pharmacology and PK studies.
She holds a PhD from the Welsh School of Pharmacy and a Certificate in Human Pharmacology from the Faculty of Pharmaceutical Medicine. Her background also includes pulmonary pharmacology and pharmacokinetic modelling.
Christopher Jeans has nearly 20 years’ experience in investigational medicinal product (IMP) management, having progressed from Research Pharmacist to Head of IMP Management, CMC Consultant and Qualified Person (QP).
Named as a QP on the UK MIA(IMP) since 2015 and the EU MIA(IMP) since 2024, he is responsible for certifying IMP batches in accordance with relevant legislation, GMP and clinical trial authorisations. He also oversees the Pharmaceutical Quality System and provides clients with quality and regulatory consultancy.
Andreas provides scientific and technical leadership and support for bioprocess teams at Cytiva. His main area of expertise is in upstream processing. Prior to joining Cytiva, Andreas was director of upstream development at Swedish Orphan Biovitrum, working on expression systems, process development for microbial and mammalian cell-based processes, and scale-up to cGMP manufacturing. During the last 20 years, Andreas has held several roles in biopharmaceutical development, including project and line management as well as manufacturing.
